NAS:XFOR (USA)
X4 Pharmaceuticals Inc $ 12.37 0.16 (1.31%)
Volume:
11,183
Avg Vol (1m):
29,740
Market Cap $:
153.77 Mil
Enterprise Value $:
92.72 Mil
P/E (TTM):
0.00
P/B:
1.65
| Net Current Asset Value | ||
| Tangible Book | ||
| Median P/S Value | ||
|
Price: $12.37 | ||
Manual of Stocks™ Web
Financial Strength | 3.4/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | 3.1 | ||
| Debt-to-Equity | 0.3 | ||
| Debt-to-EBITDA | -0.68 | ||
| Altman Z-Score | 1.17 | ||
Profitability | 1/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | -1255.8 | ||
| Net Margin % | -1271.83 | ||
| ROE % | -105.95 | ||
| ROA % | -66.4 | ||
| ROC (Joel Greenblatt) % | -3376.43 | ||
| 3-Year EBITDA Growth Rate | -9.6 | ||
| 3-Year EPS without NRI Growth Rate | -8.2 |
Ratios |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| PB Ratio | 1.65 | ||
| PS Ratio | 8.46 | ||
| EV-to-EBIT | -2.14 | ||
| EV-to-EBITDA | -2.14 | ||
| EV-to-Revenue | 26.49 | ||
| Current Ratio | 7.32 | ||
| Quick Ratio | 7.32 | ||
| Days Sales Outstanding | 161.85 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -37 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Tangible-Book | 2.54 | ||
| Price-to-Median-PS-Value | 0.77 | ||
| Earnings Yield (Greenblatt) % | -46.45 |